Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Shares Outstanding (Diluted Average) (2020 - 2025)

Puma Biotechnology's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $50.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 3.16% year-over-year to $50.7 million; the TTM value through Dec 2025 reached $50.7 million, up 3.16%, while the annual FY2025 figure was $50.7 million, 3.16% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $50.7 million in Q4 2025 per PBYI's latest filing, up from $453372.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $50.7 million in Q4 2025 to a low of $164897.0 in Q3 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $28.8 million, with a median of $41.6 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 18904.92% in 2023, then crashed 99.26% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $40.6 million in 2021, then rose by 10.56% to $44.9 million in 2022, then rose by 5.83% to $47.6 million in 2023, then grew by 3.26% to $49.1 million in 2024, then grew by 3.16% to $50.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Shares Outstanding (Diluted Average) are $50.7 million (Q4 2025), $453372.0 (Q3 2025), and $355463.0 (Q2 2025).